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The Durban Diabetes Study (DDS) is a population-based cross-sectional survey of an urban black population in the
eThekwini Municipality (city of Durban) in South Africa. The survey combines health, lifestyle and socioeconomic question-
naire data with standardised biophysical measurements, biomarkers for non-communicable and infectious diseases, and gen-
etic data. Data collection for the study is currently underway and the target sample size is 10 000 participants. The DDS has
an established infrastructure for survey ﬁeldwork, data collection and management, sample processing and storage, managed
data sharing and consent for re-approaching participants, which can be utilised for further research studies. As such, the
DDS represents a rich platform for investigating the distribution, interrelation and aetiology of chronic diseases and their risk fac-
tors, which is critical for developing health care policies for disease management and prevention. For data access enquiries please
contact the African Partnership for Chronic Disease Research (APCDR) at data@apcdr.org or the corresponding author.
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Study rationale
Infectious diseases, nutritional deﬁciencies and maternal and
neonatal conditions are the dominant contributors to the
overall burden of disease worldwide [1]. However, the bur-
den of non-communicable diseases (NCDs) such as dia-
betes, cardiovascular disease and cancer, has increased in
the last decade. In 2012, an estimated 2.8 million deaths in
sub-Saharan Africa (SSA) were attributable to NCDs; they
are projected to be the most common cause of death in
SSA by 2030 [2, 3]. The increasing prevalence of diabetes
is a key component of the global rise in NCDs. The
International Diabetes Federation currently estimates a
54% increase in global prevalence of diabetes, from 382 to
592 million by 2035 [4]. SSA is projected to have a 109% in-
crease in the prevalence of diabetes, from 19.8 million in
2013 to 41.5 million by 2035, representing the highest pro-
portional increase of any region in the world.
The rise in diabetes prevalence is thought to be a conse-
quence of rapid demographic and epidemiological transitions
and urbanisation in the region [4, 5]. Within SSA, the preva-
lence of chronic diseases such as diabetes varies markedly
among populations, suggesting that these disorders arise
from complex interrelations between environmental and
biological factors [6]. Socioeconomic and demographic dif-
ferences, diagnostic approaches, variation in lifestyle factors
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and genetic predisposition may explain some of these differ-
ences [7–9]. However, there is a lack of large-scale
population-based studies that have assessed these systemati-
cally in SSA populations. Recent population-based diabetes
studies have varied in size and scope (as shown in online
Supplementary Table S1); many have only assessed a subset
of potential risk factors, limiting comparative analyses.
Relatively few have utilised validated survey designs, such
as the WHO STEPwise approach to Surveillance (STEPS),
to capture a broadened set of variables, as in the DDS.
There is, therefore, a need for high-quality data to more re-
liably assess the burden of chronic diseases and the full spec-
trum of their risk factors, in order to determine the
individual contribution and impact of these risk factors in
SSA. In 2013, an estimated 9.3% of the population in
South Africa had diabetes, which is one of the highest
national prevalences of diabetes in SSA [10]. Studies investi-
gating the prevalence of diabetes in South Africa have
reported differing prevalence between urban and rural
areas and by ethnicity [11–14]. However, the only study
population-based epidemiological study of diabetes in
Durban was conducted in the early 1990s and found a
prevalence of 5.3% [15].
We therefore established the DDS as a population-based
research framework to investigate a broad range of lifestyle,
medical and genetic factors and their association with dia-
betes – the primary research focus of the study – together
with other chronic diseases and traits including hyperten-
sion, dyslipidaemia, human immunodeﬁciency virus (HIV)
and hepatitis C virus (HCV) in an urban South African
(black) population living in the eThekwini Municipality
(also known as the city of Durban). The study provides a re-
source to examine a wide range of research questions in
order to inform health policy and practice around the bur-
den and aetiology of chronic diseases; this in turn will enable
effective targeting of resources in South Africa and across
the region. The DDS also provides a framework for future
research including the possibility of interventional studies.
The DDS is a collaborative initiative between the
University of KwaZulu-Natal, the University of Cambridge,
the University of Oxford and the Wellcome Trust Sanger
Institute.
Study population
The study area is the eThekwini Municipality (city of
Durban) in KwaZulu-Natal, South Africa as shown in
Fig. 1. [16] Based on the 2011 population census for
South Africa, black Africans constitute 79.6% (41 000 938)
of the total population of 50.8 million [17]. KwaZulu-Natal
is the second most densely populated province in
South Africa, accounting for around one-ﬁfth of the
total population (10 267 300), of whom 86.8% are black
African, 52.3% are female and 73.7% are aged 35 years
or older [18].
The DDS sampling frame was developed independently by
the Research and Policy Department of the eThekwini
Municipality, and is divided into nine planning unit clusters
(PUCs), representing nine townships (Umlazi, Inanda,
KwaMashu, Ntuzuma, Mpumalanga Complex, Cato Manor,
Clermont, Lamontville and Chesterville). Geographic infor-
mation system mapping techniques were used to gather ac-
curate geographical and boundary data on the selected PUC
areas. The study region is predominantly urban with a total
population of approximately 1 378 750 individuals, 61% of
whom live in informal dwellings. In each PUC streets are
randomly selected, with the number of streets selected
being proportional to the size of the PUC population.
Next, within each randomly selected street, households
are nominated by systematic cluster sampling, with the num-
ber of formal or informal houses selected within each street
proportional to the ratio of formal to informal housing in
that PUC. Further, in each street the number of selected
houses is oversampled, allowing for up to 20% non-
participation without compromising overall study size.
Within each nominated household, all family members
who are of African descent, not pregnant and aged 18
years or older are eligible for recruitment into the study.
Before participant recruitment and data collection begin,
PUC areas are sensitised to the study using ﬂyers,
neighbourhood-speciﬁc community activation events and
reminders for local residents. These stages of community en-
gagement and mobilisation are conducted with the support of
the provincial department of health (KwaZulu-Natal), local
health authorities and community leaders. Once the study
rationale and procedures have been explained, all eligible indi-
viduals present at the time of mobilisation are invited to par-
ticipate in the study. A non-responder is deﬁned as an
individual who has declined an invitation to participate; a non-
Fig. 1. Map of KwaZulu-Natal and eThekwini, South Africa. The
map shows the municipal boundaries in KwaZulu-Natal, with the
eThekwini Metropolitan Municipality highlighted in red. Adapted
from Naudé et al. [16].
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response household is deﬁned as a household who has been
contacted on at least three occasions with all habitants absent
on each occasion. Each non-response household is replaced
by another house pre-selected from the same street as de-
scribed above. Data and sample collection are undertaken
at pre-arranged study appointments at a central community
venue. All study appointments occur in the morning; this is
essential as participants are required to fast overnight for a
75 g oral glucose tolerance test (OGTT).
Statistical power
The DDS sample size – based on population size, prevalence
precision estimates and power for epidemiological and gen-
etic association studies – is 10 000 participants. Previous stu-
dies in SSA have estimated a diabetes prevalence of around
10% (which is consistent with preliminary ﬁndings from our
study; data not shown). Based on this estimate, and taking
into account design effects, our sample size is sufﬁcient to
estimate the population prevalence of diabetes with a 95%
conﬁdence interval (CI) of less than 1%. For logistic re-
gression analyses that involve diabetes as an outcome,
based on 1000 cases and 9000 controls, the study has
more than 80% power to detect odds ratios (ORs) as low
as 1.2 for exposure prevalences equal to 30%. For exposure
prevalences greater than 30%, ORs less than 1.2 can be
detected with the same power. Further, for exposure preva-
lences as low as 5% the study will have more than 80%
power to detect ORs of at least 1.5. At this sample size
we will also have the ability to examine genetic variants
that explain 0.5 % of the variation in a relevant trait with
more than 80% power using a genome-wide statistical
threshold.
Data collection
The DDS collects detailed questionnaire information on par-
ticipant health, lifestyle and socioeconomic indices, as well as
biophysical measurements, biochemical, haematological and
serologic biomarkers for non-communicable and infectious
diseases, and genetic information, as shown in Table 1. The
questionnaire used in this study is an adaptation of the stan-
dardised and validated WHO STEPS tool designed for the
collection of disease risk factors [19]. The questionnaire
responses are collected on an electronic data capture system
[electronic questionnaire (EQ)]. For increased accuracy and
efﬁciency the EQ has built-in data checks, including double
entry of numbers, plausibility of answers and appropriate nu-
merical limitations, the detailed methods of which have been
previously described [20]. Biophysical measurements (height,
weight, waist and hip circumferences and blood pressure) and
samples of venous blood (baseline fasting sample, 30- and
120-min) and urine are collected in the same study appoint-
ment to maximise efﬁciency. Adhering to standardised proto-
cols, trained study personnel perform all study procedures
and sample collections. Study equipment is calibrated regu-
larly. Blood and urine samples are stored in cold boxes main-
tained at 4–8 °C until transported to a laboratory within 6 h
of collection. Full blood count, plasma glucose and HbA1c
analyses are undertaken on the day of sample collection, at
a local private laboratory. All other samples are transported
to the University of KwaZulu-Natal laboratory and processed
for storage (including centrifugation, separation into serum
and plasma, and DNA extraction). The processed samples
are stored at −70 °C for future analyses. Extracted DNA is
sent to the Wellcome Trust Sanger Institute in the UK for
next-generation genomic analyses.
Feedback of results to the participants starts during the
study appointment. All participants receive blood pressure
and body mass index results immediately, accompanied by
appropriate lifestyle and health guidance from trained
study personnel including advice to seek medical referral.
Results from the OGTT are posted to participants, unless
they choose not to receive them. Participants may also
choose to receive the results of other tests such as HIV,
HCV and liver function tests, by appointment at the DDS
feedback ofﬁce. Where participant results are abnormal, ac-
cording to clinical algorithms deﬁned in accordance with
national guidelines, participants are advised to seek further
assessment (investigation and management) at the appropri-
ate local health facility as part of their standard clinical care.
Ethical considerations
The DDS has obtained full ethical approval from the
Biomedical Research Ethics Committee at the University
of KwaZulu-Natal (reference: BF030/12) and the UK
National Research Ethics Service (reference: 14/WM/
1061). Written informed consent is obtained from all
study participants. The consent form covers the following
activities: data collection by questionnaire and biophysical
measures, sample collection and analysis including linked-
anonymous HIV testing, feedback of results, consent for
DNA extraction and genomic analyses, consent for use of
data and samples for future research, and permission to
re-approach participants for new studies.
Study progress
Data collection began in November 2013. Through success-
ful community sensitisation, engagement and mobilisation,
the study has achieved a high level of participation: to
date, 1300 individuals have been invited join the study, of
whom 96 refused participation, with a resulting response
of 92.6% (n = 1204) (Table 2). The age and sex structure
of this DDS intermediate dataset are compared with the
2011 census data for the eThekwini population in Fig. 2
[18]. Of the 1204 participants recruited to date, 28.3%
(341) are men compared with 48.2% found in the general
population census data. This low proportion of men in the
journals.cambridge.org/gheg
DDS is consistently observed in population-based studies in
South Africa. Likely explanations include high levels of un-
employment in the townships sampled leading to men mov-
ing away for work (migrant labour system) [21, 22], and
challenges in participant mobilisation as male potential parti-
cipants are often away during ofﬁce hours when the study
mobilisation takes place [11–14]. The age distribution of
the DDS intermediate dataset is broadly similar to the general
population of eThekwini: 46.6% were aged 18–34 years in the
DDS compared with 49.1% in the 2011 eThekwini census;
44.1% (DDS) compared with 43.6% (census) were aged
35–64 years; and 9.2% (DDS) compared with 7.3% (census)
were aged 65 years or older. The employment status of
DDS participants for the preceding 12 months is shown in
Fig. 3: 37.2% were in full- or part-time employment, 13.9%
were retired, and 10.2% were students. Thirty-eight per
cent of the DDS population reported being unemployed (in-
cluding both individuals able and unable to work), compared
with 30.2% in the 2011 eThekwini census.
Strengths and limitations
The DDS is a platform for population-based research
encompassing the distribution, interrelation and aetiology
Table 1. Planned data component domains in the DDS
Domain Components
Health and lifestyle questionnaire Demographic information
Education, occupation and livelihood
Socioeconomic indices (household features and ownership)
Tobacco use
Alcohol consumption
Dietary behaviour
Physical activity
Medical history
Family medical history
Biophysical measurements Blood pressure and heart rate
Height and weight
Waist circumference and hip circumference
NCD & infectious disease biomarkers and genetic data
Glycaemic biomarkers OGTT:
0-, 30-, 120-min plasma glucose
0-, 30-, 120-min serum insulin
HbA1c
Cardiometabolic and haematological biomarkers Full blood count
Total cholesterol
LDL
HDL
Lp(a)
Triglycerides
Aspartate amino transferase
Alanine amino transferase
Alkaline phosphatase
Gamma glutamyl transferase
Bilirubin
Albumin
Albumin–creatinine ratio (urine sample)
Sodium and potassium (urine sample)
Infectious disease biomarkers HIV
HBV
HCV
Genetic markers (host and pathogen) Illumina SNP chip arrays
Illumina whole genome and exome sequencing
Viral whole genome sequencing
NCD, non-communicable disease; OGTT, oral glucose tolerance test; HbA1c, glycated haemoglobin; LDL, low-density lipoprotein; HDL,
high-density lipoprotein; Lp(a), lipoprotein(a); HIV, human immunodeﬁciency virus; HBV, hepatitis B virus; HCV, hepatitis C virus; SNP,
single-nucleotide polymorphism.
journals.cambridge.org/gheg
of chronic diseases and their risk factors in an urban South
African setting, providing a valuable research resource and
creating an evidence base to inform local and national health
policy and public health programmes. The study is designed
to characterise a wide range of phenotypes – including
banked biological samples for future analyses – and to
align these with genomic data. In this way, the DDS has
the scope to address a broad set of research questions
and the ability to provide aetiological insights into the vari-
ation in risk factors for diabetes and other chronic diseases
among adults in this setting. The study has no upper age limit
for participants and is therefore well placed to investigate
disease and risk factors in older populations [23]. The sup-
port of community leaders and local residents, cultivated
through a careful and involved dialogue with these communi-
ties, enables the recruitment of informed and conﬁdent par-
ticipants who are willing to enter a survey containing sensitive
questions and encourages a high proportion of responders.
A limitation of the DDS is its cross-sectional design; it is
therefore not possible to assess incidence in this study or
the temporal association between exposures and outcomes.
However, the DDS has obtained consent to follow up and
re-approach participants, thus enabling the potential for
longitudinal studies, prospective case ascertainment of inci-
dent disease, and interventional studies. The data collection
framework of the DDS has been standardised and aligned to
the data collection framework of both the APCDR and the
pan-African Human Heredity and Health in Africa (H3A)
diabetes study [24]. This will allow future comparison with
other SSA countries, including pooled analyses of equivalent
data from existing studies (as shown in online
Supplementary Table S1) to better characterise the epidemi-
ology of diabetes in SSA.
The study speciﬁcally recruits participants of African de-
scent in order to better assess the association between
exposures and disease in this population [25, 26]. By focus-
ing on a single ethnic group, the DDS may limit its generali-
sability to other populations; this highlights the importance
of conducting similar studies nationally and across SSA to
fully understand the aetiology and determinants of chronic
disease. However, the intermediate dataset presented here
indicates that the DDS population is broadly representative
of its target population.
Future plans
The DDS continues to recruit participants towards the sam-
ple size of 10 000 participants, with sufﬁcient statistical res-
olution to present accurate prevalence estimates and
identify and assess epidemiological associations between
risk factors and disease that are informative for policy-
makers and public health programmes in the region. Given
the planned sample size, the DDS will be powered to detect
less prevalent exposures, and distinguish more subtle asso-
ciations between risk factors and disease. The ﬁnal sample
size will also have power to identify subpopulations at high
risk of chronic diseases, whilst acknowledging all the caveats
of undertaking such subgroup analyses. Additionally, with
the option to re-approach participants, the DDS has the po-
tential as a platform for future research including studies of
diabetes complications and intervention studies.
A central aim of the DDS is to combine epidemiological
methods with population-based genome-wide technologies.
This integration has already provided new insights into the
biology of chronic diseases and their risk factors in
Western populations [27]. However, the relevance of
many recent genomic ﬁndings to populations in SSA is not
known. Given the marked genomic diversity among popula-
tions in SSA, understanding the genomic basis for chronic
diseases and their risk factors in populations of African de-
scent is likely to provide additional insights into the genetic
determinants of chronic diseases and potential therapeutic
strategies [8]. The DDS is thus well positioned to take ad-
vantage of these opportunities to conduct genomic analyses
and contribute to the global genomics research arena.
Data access
All data (health, lifestyle and socioeconomic questionnaire,
biophysical measurements, NCD and infectious disease
Table 2. Demographic characteristics of participants in the DDS
intermediate dataset (n = 1204)
Variable N (%)
Sex
Men 341 (28.3)
Women 863 (71.7)
Age category (years)
18–24 284 (23.6)
25–34 277 (23.0)
35–44 189 (15.7)
45–54 198 (16.4)
55–64 144 (12.0)
65+ 111 (9.2)
Do not know 1 (0.1)
Language
isiZulu 1084 (90.0)
isiXhosa 79 (6.6)
Sesotho 28 (2.3)
Other 13 (1.1)
Level of education
Nil 16 (1.3)
Nursery or preschool 17 (1.4)
Primary 246 (20.4)
Secondary 848 (70.5)
Post-secondary/vocational 19 (1.6)
University 52 (4.3)
Do not know 6 (0.5)
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Fig. 3. Proportion of participants in the DDS intermediate dataset (n = 1204) by category of employment in the preceding 12 months.
Fig. 2. Population pyramid comparing the age and sex structure of the DDS intermediate dataset (n = 1204) with the 2011 census
population for the eThekwini municipality (city of Durban). DDS data for women (red bars) and men (blue bars) are superimposed over
census data for women (black and white bars, hatched) and men (black and white bars, plain).
journals.cambridge.org/gheg
biomarkers and genetic) generated in the DDS are stored
and curated as part of the APCDR. For data access inquiries
you may contact the APCDR data access committee (data@
apcdr.org).
Supplementary material
To view supplementary material for this article, please visit
http://dx.doi.org/10.1017/gheg.2015.3
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